Masoud Maher 4

Accession 0001209191-21-064891

CIK 0001287098other

View on SEC.gov Company Profile

Filed

Nov 15, 7:00 PM ET

Accepted

Nov 16, 7:14 PM ET

Size

25.0 KB

Accession

0001209191-21-064891

Insider Transaction Report

Form 4

Period: 2021-11-12

MAXCYTE, INC.MXCT

Masoud Maher

DirectorPresident and CEO

Transactions

Exercise/Conversion
Employee Stock Option (right to buy)
2021-11-16−18,562→ 0 total
Exercise: $3.25Exp: 2027-07-14→ Common Stock (18,562 underlying)
Exercise/Conversion
Common Stock
2021-11-12$2.08/sh+25,722$53,502→ 25,722 total
Exercise/Conversion
Common Stock
2021-11-15$3.25/sh+6,438$20,924→ 30,716 total
Sale
Common Stock
2021-11-15$12.16/sh−30,716$373,507→ 0 total
Exercise/Conversion
Employee Stock Option (right to buy)
2021-11-15−24,278→ 75,000 total
Exercise: $2.08Exp: 2030-02-25→ Common Stock (24,278 underlying)
Exercise/Conversion
Employee Stock Option (right to buy)
2021-11-15−6,438→ 18,562 total
Exercise: $3.25Exp: 2027-07-14→ Common Stock (6,438 underlying)
Exercise/Conversion
Employee Stock Option (right to buy)
2021-11-12−25,722→ 99,278 total
Exercise: $2.08Exp: 2030-02-25→ Common Stock (25,722 underlying)
Sale
Common Stock
2021-11-12$12.66/sh−25,722$325,641→ 0 total
Exercise/Conversion
Common Stock
2021-11-15$2.08/sh+24,278$50,498→ 24,278 total
Exercise/Conversion
Common Stock
2021-11-16$3.25/sh+18,562$60,327→ 18,562 total
Sale
Common Stock
2021-11-16$12.08/sh−18,562$224,229→ 0 total

Footnotes (6)

[F1]This exercise price is in U.S. Dollars and reflects the conversion of GBP to USD at an exchange rate of GBP 1.00 to $1.34.
[F2]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.56 to $12.765, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
[F3]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.03 to $12.615, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
[F4]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.20, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
[F5]The shares underlying this option vested or shall vest monthly in forty-eight (48) equal monthly installments commencing on March 25, 2020, subject to the Reporting Person's continued service to the Issuer through each vesting date.
[F6]This option is fully vested and exercisable.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

MAXCYTE, INC.

CIK 0001287098

→

Entity typeother

Related Parties

filerCIK 0001874571

Filing Metadata

Form type: 4
Filed: Nov 15, 7:00 PM ET
Accepted: Nov 16, 7:14 PM ET
Size: 25.0 KB

View on SEC.gov